FindTrial
Sign In

Detecting Rare Cancer Cells and DNA in blood samples of Early-Stage Triple-Negative Breast Cancer After Chemotherapy

Evaluation of circulating tumor DNA (ctDNA) and Circulating Tumor Cells (CTC) for detecting Minimal Residual Disease in Early-Stage Triple-Negative Breast Cancer Post-Neoadjuvant Chemotherapy. - REACT is a trial Acronym. REACT - (R)esidual (E)valuation (A)fter (C)hemotherapy in (T)NBC.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/12/078366
Enrollment
50
Registered
2024-12-20
Start date
Unknown
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C50- Malignant neoplasm of breast

Interventions

Intervention1: OncoDiscover, OncoIndx, OncoRADAR.: This observational study involves the collection and analysis of blood samples from participants at different time points to assess the presence of c

Sponsors

OneCell Diagnostics
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosis: Confirmed early-stage triple-negative breast cancer (TNBC). Treatment: Eligible for neoadjuvant chemotherapy (NACT) for TNBC. Age: Females 18 and above Consent: Able and willing to provide informed consent. Organ Function: Adequate liver, renal, and blood counts. Follow-up Compliance: Willingness for regular follow-up and blood sampling. Baseline Sample: Available baseline blood sample pre-NACT.

Exclusion criteria

Exclusion criteria: Metastatic Disease: Presence of metastatic breast cancer. Previous Malignancies: Other malignancies within a specified recent period. Concurrent Trials: Participation in other clinical trials with investigational drugs. Major Health Conditions: Uncontrolled diabetes, severe cardiovascular diseases, or infections. Pregnancy/Breastfeeding: Currently pregnant or breastfeeding.

Design outcomes

Primary

MeasureTime frame
i. Pathological Complete Response (pCR) ii. Overall Survival (OS) iii. Progression-Free Survival (PFS): iv. Disease-Free Survival (DFS):Timepoint: 3 years—

Secondary

MeasureTime frame
i. Recurrence Rate ii. CTC and ctDNA Levels Correlation with Survival Outcomes iii. Time to Recurrence iv. Biomarker DynamicsTimepoint: 3 years—

Countries

India

Contacts

Public ContactDr Bhuvan Chugh

Max Super Speciality Hospital Saket (East Block) (A unit of Devki Devi Foundation)

drbhuvanchugh@gmail.com8607773444

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026